Myelofibrosis Archives - Hematology Advisor

General Hematology

Parsaclisib Improved Myelofibrosis Symptoms in Patients With Suboptimal Response to Ruxolitinib

By

Sucharita Mistry, PhD

October 13, 2021

At 12 weeks, most patients had a reduction in spleen volume.

Anemia

LCL161 Shows Moderately Positive Objective Response Rate in Patients With Myelofibrosis

By

Jonathan Goodman, MPhil

September 17, 2021

Researchers sought to determine whether LCL161 would induce a response in patients with myelofibrosis.

General Hematology

Depression Common Among Patients With a Myeloproliferative Neoplasm

By

Susan Moench, PhD, PA-C

October 30, 2020

Using validated tools, investigators determined that patients with a MPN were likely to experience significant symptoms of depression.

Woman extracting a pill from the blister

General Hematology

Cutaneous AEs Are Common in Patients With MPNs Treated With Hydroxyurea

By

Susan Moench, PhD, PA-C

July 29, 2020

Previously conducted retrospective studies may have underestimated the incidence of hydroxyurea-related skin toxicity in patients with MPNs.

EHA25 Virtual Congress

Characteristics of Ruxolitinib Discontinuation Syndrome in Myelofibrosis

By

Andrea S. Blevins Primeau, PhD, MBA

June 17, 2020

Ruxolitinib discontinuation syndrome was associated with spleen length and platelet count, although severe cases were rare in a cohort of patients with myelofibrosis.

Bone marrow biopsy from myelodysplastic condition under the microscope view. Histology tissue of bone marrow biopsy.

General Hematology

Study Results Find Interaction Between Fedratinib and a Strong Inhibitor of CYP3A4

By

Susan Moench, PhD, PA-C

April 28, 2020

Fedratinib, a selective inhibitor of JAK2, was approved in 2019 by the US FDA for the treatment of certain groups of patients with myelofibrosis.

General Hematology

Management of Patients With Myelofibrosis Experiencing Ruxolitinib Failure

By

Susan Moench, PhD, PA-C

April 8, 2020

Identification of the underlying pattern for ruxolitinib failure in patients with myelofibrosis is a significant factor in determining appropriate treatment.

A recent article is only the latest in a series of studies drawing attention to the importance of di

General Hematology

Second Cancers Pose Significant Mortality Risk in Myeloproliferative Neoplasms

By

Jonathan Goodman, MPhil

March 24, 2020

Researchers sought to determine whether second cancers associated with MPNs affect a patient’s prognosis, and whether cytoreductive or antiplatelet therapies affect outcomes.